There is currently one preclinical study evaluating SUR1-TRPM4 and glibenclamide in an in vivo model of status epilepticus, the results of which suggest that inhibition is beneficial in treating cerebral edema as well as improving outcomes [188]. Here, TRPM4 is linked to status epilepticus.